{"id":18712,"date":"2025-08-01T10:24:54","date_gmt":"2025-08-01T10:24:54","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=18712"},"modified":"2025-08-01T10:24:54","modified_gmt":"2025-08-01T10:24:54","slug":"lantern-pharma-completes-lp-300-lung-cancer-trial-signup","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/lantern-pharma-completes-lp-300-lung-cancer-trial-signup\/","title":{"rendered":"\u30e9\u30f3\u30bf\u30f3\u30fb\u30d5\u30a1\u30fc\u30de\u3001LP-300 \u80ba\u304c\u3093\u81e8\u5e8a\u8a66\u9a13\u306e\u5951\u7d04\u3092\u5b8c\u4e86"},"content":{"rendered":"

\u4eba\u5de5\u77e5\u80fd\uff08AI\uff09\u4f01\u696d\u3067\u3042\u308b\u30e9\u30f3\u30bf\u30f3\u30d5\u30a1\u30fc\u30de\u682a\u5f0f\u4f1a\u793e\uff08\u672c\u793e\uff1a\u6771\u4eac\u90fd\u5343\u4ee3\u7530\u533a\u3001\u4ee3\u8868\u53d6\u7de0\u5f79\u793e\u9577\uff1a\u8fbb\u672c\u90a6\u5f66\u3001\u4ee5\u4e0b\u300c\u30e9\u30f3\u30bf\u30f3\u30d5\u30a1\u30fc\u30de\u300d\uff09\u306f\u3001\u72ec\u81ea\u306eAI\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u300cRADR\u00ae\u300d\u3092\u6d3b\u7528\u3057\u305f\u304c\u3093\u6a19\u7684\u6cbb\u7642\u85ac\u306e\u958b\u767a\u3092\u9032\u3081\u3066\u3044\u308b\u30e9\u30f3\u30bf\u30f3\u30d5\u30a1\u30fc\u30de\u682a\u5f0f\u4f1a\u793e\uff08\u672c\u793e\uff1a\u6771\u4eac\u90fd\u5343\u4ee3\u7530\u533a\u3001\u4ee3\u8868\u53d6\u7de0\u5f79\u793e\u9577\uff1a\u8fbb\u672c\u90a6\u5f66\u3001\u4ee5\u4e0b\u300c\u30e9\u30f3\u30bf\u30f3\u30d5\u30a1\u30fc\u30de\u300d\uff09\u304c\u3001\u65e5\u672c\u306b\u304a\u3051\u308b\u7b2c2\u76f8\u81e8\u5e8a\u8a66\u9a13\u300cHARMONIC\u2122\u300d\u306e\u5bfe\u8c61\u60a3\u8005\u767b\u9332\u304c\u5b8c\u4e86\u3057\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u540c\u793e\u306f\u3001\u56fd\u7acb\u304c\u3093\u7814\u7a76\u30bb\u30f3\u30bf\u30fc\u304c\u3093\u5bfe\u7b56\u60c5\u5831\u30bb\u30f3\u30bf\u30fc\u3092\u542b\u3080\u56fd\u5185\u306e5\u3064\u306e\u81e8\u5e8a\u65bd\u8a2d\u3067\u3001\u4e88\u5b9a\u3088\u308a\u65e9\u304f10\u540d\u306e\u60a3\u8005\u3092\u767b\u9332\u3057\u307e\u3057\u305f\u3002<\/p>\n

HARMONIC\u2122 \u8a66\u9a13\u306f\u3001\u30c1\u30ed\u30b7\u30f3\u30ad\u30ca\u30fc\u30bc\u963b\u5bb3\u5264\uff08TKI\uff09\u306b\u3088\u308b\u6cbb\u7642\u5f8c\u306b\u9032\u884c\u3057\u305f\u975e\u5c0f\u7d30\u80de\u80ba\u304c\u3093 \uff08NSCLC\uff09\u306e\u672a\u55ab\u7159\u60a3\u8005\u3092\u5bfe\u8c61\u306b\u3001\u30ab\u30eb\u30dc\u30d7\u30e9\u30c1\u30f3\u304a\u3088\u3073\u30da\u30e1\u30c8\u30ec\u30ad\u30bb\u30c9\u3068\u306e\u4f75\u7528\u3067 LP-300 \u3092\u8a55\u4fa1\u3059\u308b\u3082\u306e\u3067\u3059\u3002\u4eca\u56de\u306e\u65e5\u672c\u3067\u306e\u767b\u9332\u306e\u6210\u529f\u306f\u3001\u65e5\u672c\u3084\u53f0\u6e7e\u306e\u3088\u3046\u306a\u975e\u55ab\u7159\u8005NSCLC\u60a3\u8005\u306e\u5272\u5408\u304c\u8457\u3057\u304f\u9ad8\u3044\u5730\u57df\u306b\u672c\u8a66\u9a13\u3092\u56fd\u969b\u7684\u306b\u62e1\u5927\u3059\u308b\u3068\u3044\u3046\u30e9\u30f3\u30bf\u30f3\u793e\u306e\u6226\u7565\u7684\u6c7a\u5b9a\u3092\u691c\u8a3c\u3059\u308b\u3082\u306e\u3067\u3059\u3002<\/p>\n

\u300c\u30e9\u30f3\u30bf\u30f3\u30fb\u30d5\u30a1\u30fc\u30de\u306e\u793e\u9577\u517c\u6700\u9ad8\u7d4c\u55b6\u8cac\u4efb\u8005\uff08CEO\uff09\u3067\u3042\u308b\u30d1\u30ca\u30fb\u30b7\u30e3\u30eb\u30de\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002 \u300c\u65e5\u672c\u3067\u306e\u76ee\u6a19\u75c7\u4f8b\u767b\u9332\u304c\u4e88\u5b9a\u3088\u308a\u65e9\u304f\u5b8c\u4e86\u3057\u305f\u3053\u3068\u306f\u3001\u5f53\u793e\u306e\u56fd\u969b\u5c55\u958b\u6226\u7565\u306e\u512a\u308c\u305f\u5b9f\u884c\u3092\u793a\u3059\u3068\u540c\u6642\u306b\u3001\u975e\u55ab\u7159\u8005 NSCLC \u306e\u6709\u75c5\u7387\u304c\u6700\u3082\u9ad8\u3044\u5730\u57df\u306b\u7126\u70b9\u3092\u5f53\u3066\u308b\u3068\u3044\u3046\u5f53\u793e\u306e\u6c7a\u65ad\u3092\u5b9f\u8a3c\u3059\u308b\u3082\u306e\u3067\u3059\u3002\u300c\u3053\u306e\u6210\u679c\u306f\u3001\u53f0\u6e7e\u3068\u7c73\u56fd\u3067\u767b\u9332\u3092\u7d99\u7d9a\u3057\u3001LP-300 \u304c\u30a2\u30f3\u30e1\u30c3\u30c8\u30fb\u30e1\u30c7\u30a3\u30ab\u30eb\u30fb\u30cb\u30fc\u30ba\u306e\u9ad8 \u3044\u3001\u5341\u5206\u306a\u6cbb\u7642\u3092\u53d7\u3051\u3066\u3044\u306a\u3044\u60a3\u8005\u96c6\u56e3\u306e\u6cbb\u7642\u9078\u629e\u80a2\u3068\u3057\u3066\u78ba\u7acb\u3059\u308b\u305f\u3081\u306e\u81e8\u5e8a\u30c7\u30fc\u30bf\u53d6\u5f97\u306b\u8fd1\u3065\u3044 \u305f\u3053\u3068\u3092\u793a\u3059\u3082\u306e\u3067\u3059\u300d\u3068\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002<\/p>\n

\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a \u30d7\u30ed\u30bf\u30b8\u30a7\u30cb\u30c3\u30af\u304c\u30b9\u30c6\u30a3\u30eb\u30d9\u30ce\u30a4\u30c9\u533b\u85ac\u54c1\u306e\u65e5\u672c\u7279\u8a31\u3092\u53d6\u5f97<\/a><\/h4>\n

\u65e5\u672c\u3067\u306e\u767b\u9332\u5b8c\u4e86\u306f\u3001\u30b0\u30ed\u30fc\u30d0\u30eb\u306a HARMONIC\u2122 \u8a66\u9a13\u306e\u91cd\u8981\u306a\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u3068\u306a\u308a\u307e\u3059\u3002\u65e5\u672c\u306f\u3001\u6b27\u7c73\u306e\u60a3\u8005\u6570\uff08\u901a\u5e38 15%\uff09\u306b\u6bd4\u3079\u3001\u55ab\u7159\u6b74\u306e\u306a\u3044 NSCLC \u60a3\u8005\u306e\u5272\u5408\uff08\u65b0\u898f\u75c7\u4f8b\u306e 33-40%\uff09\u304c\u8457\u3057\u304f\u9ad8\u304f\u3001\u672c\u8a66\u9a13\u306b\u3068\u3063\u3066\u6226\u7565\u7684\u306b\u91cd\u8981\u306a\u5730\u57df\u3067\u3059\u3002\u540c\u69d8\u306b\u3001\u80ba\u304c\u3093\u60a3\u8005\u306e50%\u4ee5\u4e0a\u304c\u975e\u55ab\u7159\u8005\u3067\u3042\u308b\u53f0\u6e7e\u3082\u3001\u91cd\u8981\u306a\u767b\u9332\u5730\u57df\u3067\u3059\u3002<\/p>\n

HARMONIC\u2122 \u8a66\u9a13\u3067\u306f\u3001\u7c73\u56fd\u3067\u6700\u521d\u306b\u767b\u9332\u3055\u308c\u305f 7 \u4f8b\u306e\u60a3\u8005\u3055\u3093\u306b\u304a\u3044\u3066\u300186% \u306e\u81e8\u5e8a\u7684\u6709\u52b9\u7387\u3068 43% \u306e\u5ba2\u89b3\u7684\u594f\u52b9\u7387\u3092\u793a\u3057\u3001\u6700\u521d\u306e\u5b89\u5168\u6027\u30ea\u30fc\u30c9\u30a4\u30f3\u30b3\u30db\u30fc\u30c8\u3067\u6709\u671b\u306a\u7d50\u679c\u3092\u793a\u3057\u307e\u3057\u305f\u3002\u7279\u306b\u6700\u8fd1\u306e\u30c7\u30fc\u30bf\u3067\u306f\u30011\u540d\u306e\u60a3\u8005\u304c\u6a19\u7684\u304c\u3093\u75c5\u5909\u306b\u304a\u3044\u3066\u6301\u7d9a\u7684\u5b8c\u5168\u594f\u52b9\u3092\u9054\u6210\u3057\u3001\u751f\u5b58\u304c2\u5e74\u8fd1\u304f\u7d9a\u3044\u3066\u3044\u308b\u3053\u3068\u304c\u660e\u3089\u304b\u306b\u306a\u308a\u3001LP-300\u304c\u672a\u55ab\u7159\u306eNSCLC\u60a3\u8005\u306b\u3068\u3063\u3066\u6709\u610f\u7fa9\u306a\u9577\u671f\u7684\u8ee2\u5e30\u3092\u3082\u305f\u3089\u3059\u53ef\u80fd\u6027\u304c\u793a\u3055\u308c\u307e\u3057\u305f\u3002<\/p>\n

\u975e\u55ab\u7159\u8005NSCLC\u306f\u3001\u30e6\u30cb\u30fc\u30af\u306a\u81e8\u5e8a\u7684\u30fb\u30b2\u30ce\u30e0\u7684\u7279\u5fb4\u3092\u6709\u3059\u308b\u5225\u500b\u306e\u75be\u60a3\u3067\u3042\u308b\u3068\u8a8d\u8b58\u3055\u308c\u3064\u3064\u3042\u308a1\u3002\u73fe\u5728\u3001\u975e\u55ab\u7159\u8005NSCLC\u60a3\u8005\u5411\u3051\u306b\u7279\u5225\u306b\u627f\u8a8d\u3055\u308c\u305f\u6cbb\u7642\u85ac\u306f\u306a\u304f\u3001\u3053\u306e\u96c6\u56e3\u304c\u76f4\u9762\u3057\u3066\u3044\u308b\u91cd\u5927\u306a\u30a2\u30f3\u30e1\u30c3\u30c8\u30fb\u30e1\u30c7\u30a3\u30ab\u30eb\u30fb\u30cb\u30fc\u30ba\u3092\u6d6e\u304d\u5f6b\u308a\u306b\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n

\u30e9\u30f3\u30bf\u30f3\u306f\u3001LP-300\u306e\u5546\u696d\u7684\u53ef\u80fd\u6027\u3092\u8907\u6570\u306e\u5730\u57df\u3067\u6700\u5927\u5316\u3059\u308b\u305f\u3081\u3001\u5171\u540c\u7814\u7a76\u3084\u63d0\u643a\u306e\u6a5f\u4f1a\u3092\u7a4d\u6975\u7684\u306b\u63a2\u3063\u3066\u3044\u307e\u3059\u3002 \u30e9\u30f3\u30bf\u30f3<\/a> HARMONIC\u2122 \u8a66\u9a13\u306e\u3055\u3089\u306a\u308b\u81e8\u5e8a\u30c7\u30fc\u30bf\u304a\u3088\u3073\u8ee2\u5e30\u30c7\u30fc\u30bf\u306b\u3064\u3044\u3066\u306f\u3001\u30a2\u30b8\u30a2\u3068\u7c73\u56fd\u306e\u60a3\u8005\u30b3\u30db\u30fc\u30c8\u3092\u5bfe\u8c61\u3068\u3057\u305f\u6700\u65b0\u60c5\u5831\u3092\u4eca\u671f\u5f8c\u534a\u306b\u63d0\u4f9b\u3059\u308b\u4e88\u5b9a\u3067\u3059\u3002<\/p>\n

\u30bd\u30fc\u30b9 \u30d3\u30b8\u30cd\u30b9\u30ef\u30a4\u30e4\u30fc<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"

Lantern Pharma Inc., an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR\u00ae AI platform, announced the successful completion of targeted enrollment for its Phase 2 HARMONIC\u2122 clinical trial in Japan. The company enrolled 10 patients ahead of schedule across five clinical sites in Japan, including the National Cancer Center Japan. The HARMONIC\u2122 trial is evaluating LP-300 in combination with carboplatin and pemetrexed in never-smoker patients with non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with tyrosine kinase inhibitors (TKIs). The successful Japanese enrollment validates Lantern’s strategic decision to expand the trial internationally to regions with significantly higher rates of never-smoker NSCLC patients such […]<\/p>\n","protected":false},"author":4,"featured_media":18754,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[208,89,211,237,182,206],"tags":[6731,6730,424,6728,6729],"ppma_author":[205],"class_list":{"0":"post-18712","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-apac","8":"category-health-tech","9":"category-japan","10":"category-news","11":"category-pharma","12":"category-regional","13":"tag-lantern-pharma","14":"tag-lung-cancer","15":"tag-pharma","16":"tag-phase-2-harmonic","17":"tag-radr-ai-platform"},"yoast_head":"\nLantern Pharma Finalizes LP-300 Phase 2 Lung Trial in Japan<\/title>\n<meta name=\"description\" content=\"Lantern Pharma has completed enrollment ahead of schedule for its Phase 2 HARMONIC lung cancer trial in Japan using its RADR AI platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/lantern-pharma-completes-lp-300-lung-cancer-trial-signup\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lantern Pharma Finalizes LP-300 Phase 2 Lung Trial in Japan\" \/>\n<meta property=\"og:description\" content=\"Lantern Pharma has completed enrollment ahead of schedule for its Phase 2 HARMONIC lung cancer trial in Japan using its RADR AI platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/lantern-pharma-completes-lp-300-lung-cancer-trial-signup\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-01T10:24:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/08\/Lantern-Pharma-Completes-Targeted-Enrollment-for-Lung-Cancer-Phase-2-Harmonic\u2122-Clinical-Trial-in-Japan-for-LP-300.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NewsDesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"NewsDesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30e9\u30f3\u30bf\u30f3\u30fb\u30d5\u30a1\u30fc\u30de\u3001\u65e5\u672c\u3067LP-300\u80ba\u306e\u7b2c2\u76f8\u81e8\u5e8a\u8a66\u9a13\u3092\u7d42\u4e86","description":"\u30e9\u30f3\u30bf\u30f3\u30fb\u30d5\u30a1\u30fc\u30de\u306f\u3001AI\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u300cRADR\u300d\u3092\u7528\u3044\u305f\u80ba\u304c\u3093\u30d5\u30a7\u30fc\u30ba2\u8a66\u9a13\u300cHARMONIC\u300d\u306b\u304a\u3044\u3066\u3001\u65e5\u672c\u3067\u306e\u88ab\u9a13\u8005\u767b\u9332\u3092\u4e88\u5b9a\u3088\u308a\u65e9\u304f\u5b8c\u4e86\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/lantern-pharma-completes-lp-300-lung-cancer-trial-signup\/","og_locale":"ja_JP","og_type":"article","og_title":"Lantern Pharma Finalizes LP-300 Phase 2 Lung Trial in Japan","og_description":"Lantern Pharma has completed enrollment ahead of schedule for its Phase 2 HARMONIC lung cancer trial in Japan using its RADR AI platform.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/lantern-pharma-completes-lp-300-lung-cancer-trial-signup\/","og_site_name":"itbusinesstoday","article_published_time":"2025-08-01T10:24:54+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/08\/Lantern-Pharma-Completes-Targeted-Enrollment-for-Lung-Cancer-Phase-2-Harmonic\u2122-Clinical-Trial-in-Japan-for-LP-300.webp","type":"image\/webp"}],"author":"NewsDesk","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"NewsDesk","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"3\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/lantern-pharma-completes-lp-300-lung-cancer-trial-signup\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/lantern-pharma-completes-lp-300-lung-cancer-trial-signup\/"},"author":{"name":"NewsDesk","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812"},"headline":"Lantern Pharma completes LP-300 Lung cancer trial signup","datePublished":"2025-08-01T10:24:54+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/lantern-pharma-completes-lp-300-lung-cancer-trial-signup\/"},"wordCount":442,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/lantern-pharma-completes-lp-300-lung-cancer-trial-signup\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/08\/Lantern-Pharma-Completes-Targeted-Enrollment-for-Lung-Cancer-Phase-2-Harmonic\u2122-Clinical-Trial-in-Japan-for-LP-300.webp","keywords":["Lantern Pharma","Lung Cancer","Pharma","Phase 2 HARMONIC","RADR AI platform"],"articleSection":["APAC","Health Tech","Japan","News","Pharma","Regional"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/lantern-pharma-completes-lp-300-lung-cancer-trial-signup\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/lantern-pharma-completes-lp-300-lung-cancer-trial-signup\/","name":"\u30e9\u30f3\u30bf\u30f3\u30fb\u30d5\u30a1\u30fc\u30de\u3001\u65e5\u672c\u3067LP-300\u80ba\u306e\u7b2c2\u76f8\u81e8\u5e8a\u8a66\u9a13\u3092\u7d42\u4e86","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/lantern-pharma-completes-lp-300-lung-cancer-trial-signup\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/lantern-pharma-completes-lp-300-lung-cancer-trial-signup\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/08\/Lantern-Pharma-Completes-Targeted-Enrollment-for-Lung-Cancer-Phase-2-Harmonic\u2122-Clinical-Trial-in-Japan-for-LP-300.webp","datePublished":"2025-08-01T10:24:54+00:00","description":"\u30e9\u30f3\u30bf\u30f3\u30fb\u30d5\u30a1\u30fc\u30de\u306f\u3001AI\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u300cRADR\u300d\u3092\u7528\u3044\u305f\u80ba\u304c\u3093\u30d5\u30a7\u30fc\u30ba2\u8a66\u9a13\u300cHARMONIC\u300d\u306b\u304a\u3044\u3066\u3001\u65e5\u672c\u3067\u306e\u88ab\u9a13\u8005\u767b\u9332\u3092\u4e88\u5b9a\u3088\u308a\u65e9\u304f\u5b8c\u4e86\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/lantern-pharma-completes-lp-300-lung-cancer-trial-signup\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/pharma\/lantern-pharma-completes-lp-300-lung-cancer-trial-signup\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/lantern-pharma-completes-lp-300-lung-cancer-trial-signup\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/08\/Lantern-Pharma-Completes-Targeted-Enrollment-for-Lung-Cancer-Phase-2-Harmonic\u2122-Clinical-Trial-in-Japan-for-LP-300.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/08\/Lantern-Pharma-Completes-Targeted-Enrollment-for-Lung-Cancer-Phase-2-Harmonic\u2122-Clinical-Trial-in-Japan-for-LP-300.webp","width":1200,"height":800,"caption":"Lantern-Pharma"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/lantern-pharma-completes-lp-300-lung-cancer-trial-signup\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Lantern Pharma completes LP-300 Lung cancer trial signup"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812","name":"\u30cb\u30e5\u30fc\u30b9\u30c7\u30b9\u30af","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png74f313ad3d6fa27a1eee85c30be63d03","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","caption":"NewsDesk"},"sameAs":["https:\/\/itbusinesstoday.com"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/newsdesk\/"}]}},"authors":[{"term_id":205,"user_id":4,"is_guest":0,"slug":"newsdesk","display_name":"NewsDesk","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/18712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=18712"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/18712\/revisions"}],"predecessor-version":[{"id":18713,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/18712\/revisions\/18713"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/18754"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=18712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=18712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=18712"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=18712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}